scholarly article | Q13442814 |
P356 | DOI | 10.1016/J.DRUP.2004.03.003 |
P698 | PubMed publication ID | 15158765 |
P2093 | author name string | Daria J Hazuda | |
Michael D Miller | |||
P433 | issue | 2 | |
P304 | page(s) | 89-95 | |
P577 | publication date | 2004-04-01 | |
P1433 | published in | Drug Resistance Updates | Q3040081 |
P1476 | title | HIV resistance to the fusion inhibitor enfuvirtide: mechanisms and clinical implications | |
P478 | volume | 7 |
Q37153758 | Addition of a cholesterol group to an HIV-1 peptide fusion inhibitor dramatically increases its antiviral potency |
Q39698701 | An optimized MM/PBSA virtual screening approach applied to an HIV-1 gp41 fusion peptide inhibitor. |
Q34332580 | Antiviral drugs specific for coronaviruses in preclinical development |
Q34315133 | Cell-type specific requirements for thiol/disulfide exchange during HIV-1 entry and infection |
Q33943822 | Covalent stabilization of coiled coils of the HIV gp41 N region yields extremely potent and broad inhibitors of viral infection |
Q36558109 | Current developments in HIV chemotherapy |
Q36150601 | Emerging anti-HIV drugs |
Q36237524 | Emerging drug targets for antiretroviral therapy |
Q39389791 | Enfuvirtide resistance mutations: impact on human immunodeficiency virus envelope function, entry inhibitor sensitivity, and virus neutralization |
Q92081948 | Massively Parallel Profiling of HIV-1 Resistance to the Fusion Inhibitor Enfuvirtide |
Q34725136 | Novel inhibitors of severe acute respiratory syndrome coronavirus entry that act by three distinct mechanisms |
Q44113439 | Specific enfuvirtide-associated mutational pathways in HIV-1 Gp41 are significantly correlated with an increase in CD4(+) cell count, despite virological failure |
Q35741691 | The tyrosine kinase inhibitor genistein blocks HIV-1 infection in primary human macrophages |
Q40444598 | The virion-associated Gag-Pol is decreased in chimeric Moloney murine leukemia viruses in which the readthrough region is replaced by the frameshift region of the human immunodeficiency virus type 1. |
Q37247695 | Treatment with the fusion inhibitor enfuvirtide influences the appearance of mutations in the human immunodeficiency virus type 1 regulatory protein rev. |
Search more.